The Cigna Group (CI), headquartered in Bloomfield, Connecticut, is a global healthcare company with a market capitalization of approximately $79.4 billion. Founded in 1792, the company serves more than 185 million customer relationships across over 30 markets and jurisdictions.
Its business operates through Cigna Healthcare and Evernorth Health Services. While Cigna Healthcare provides medical, dental, behavioral health, and insurance solutions to individuals, families, and employers, Evernorth focuses on pharmacy benefits, specialty pharmacy services, drug distribution, and healthcare management programs. The company reaches customers through employers, brokers, consultants, and public and private healthcare exchanges, offering a broad range of healthcare and related services.
However, Cigna’s business strength has not fully translated into stock market performance. Shares of this leading healthcare company have surged 9.5% over the past 52 weeks, trailing the S&P 500 Index ($SPX), which has advanced 10.8%. The gap is also visible in 2026 so far, with Cigna up 7.6% on a year-to-date (YTD) basis, compared with the benchmark’s 10.9% gain.
The comparison looks even less flattering against the iShares U.S. Healthcare Providers ETF (IHF), which rose 23.5% over the past year and 26% YTD.
Cigna’s stock story in 2026 has been a bit of a mixed bag. Shares have stayed in positive territory, but the gains have not kept pace with the broader market. Strong earnings, repeated Wall Street beats, and an upgraded full-year outlook have provided some support.
However, the optimism took a hit after the Nov. 5 Q3 results, when shares slipped despite beating revenue and earnings estimates. The bigger concern was what lies ahead. Management flagged several 2027 challenges, including declining pharmacy membership, weaker pharmacy benefit earnings, its ACA market exit, and a slower specialty drug pipeline.
Analysts tracking Cigna project its EPS to rise 2.9% year over year to $30.71 for the fiscal year ending in December 2026. Cigna has surpassed consensus EPS estimates in each of the past four quarters, maintaining a steady track record of delivering stronger-than-expected results.
Based on the 23 analysts covering CI stock, the consensus rating is a “Moderate Buy.” The rating is based on 14 “Strong Buy” ratings, three “Moderate Sell” ratings, and six “Hold” ratings.
The configuration has been constant over the past few months.
Most recently, Wells Fargo raised CI’s price target to $325 from $307 and maintained an “Equal Weight” rating.
Based on analysts’ estimates, the mean price target of $347.17 implies a 17.2% premium to CI’s current share price, while the Street-high price target of $400 suggests 35% upside potential.
On the date of publication, Sristi Suman Jayaswal did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.